Summer Sessions 7: Dr. Randall Schatzman & The New Fundraising Norm

We love to hear from our listeners. Send us a message. Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, discusses his company's adjustment to pandemic disruption on the fundraising trail. He walks us through the remote-fundraising strategy that landed Bolt's recent $93.5 million Series C financing round, and how the company is moving towards an IPO in spite of market, civil, and political tumult. Access this and hundreds of episodes of the Business of Biotech videocast under the Listen &...